Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules

Core Viewpoint - Annovis Bio, Inc. has announced a registered direct offering of 1,670,732 shares of its common stock at a price of $2.05 per share, aiming to raise approximately $3.4 million for working capital and general corporate purposes [1][2]. Group 1: Offering Details - The offering price of $2.05 per share reflects the closing price on October 24, 2025 [1]. - The total gross proceeds from the offering are expected to be around $3.4 million before deducting fees and expenses [2]. - H.C. Wainwright & Co. is acting as the exclusive placement agent for this offering [2]. Group 2: Company Background - Annovis Bio is focused on developing therapies for neurodegenerative diseases, including Alzheimer's disease (AD) and Parkinson's disease (PD) [5]. - The company is headquartered in Malvern, Pennsylvania, and is committed to improving patient outcomes and quality of life through innovative therapies [5]. Group 3: Regulatory Information - The securities are being offered under a "shelf" registration statement previously filed with the SEC, which became effective on February 12, 2024 [3]. - A prospectus supplement related to the offering will be filed with the SEC and will be available on their website [3].